CDEK
← All drugs Report issue

ticagrelor

Trade name: brilinta

Small moleculeapproved

Approved

Jul 20, 2011

Ticagrelor (known trade names Brilinta, Brilique and Possia) is a P2Y12 platelet inhibitor. Brilinta has been approved by the US Food and Drug administration (FDA) in 2011 and is indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. Brilinta also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS. Ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation. Ticagrelor and its active metabolite are approximately equipotent. In vitro metabolism studies demonstrate that ticagrelor and its major active metabolite are weak inhibitors of CYP3A4, potential activators of CYP3A5 and inhibitors of the P-gp transporter. Most common adverse reactions are bleeding 12% and dyspnea 14%. — NCATS

Clinical trial activity

407 trials · 305 clinical orgs · 19 marketing orgs

Phase 1
42
Phase 2
113
Phase 3
93
Phase 4
208

Earliest trial started Oct 1, 2006 (NCT00391872)

Timeline

2000s

  1. Jan 1, 2006

    AstraZeneca — Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2007

    AstraZeneca — Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2007

    AstraZeneca — Earliest Phase 2 Sponsor(trial)

2010s

  1. Jul 20, 2011

    AstraZeneca — Earliest FDA Approval

  2. Jul 20, 2011

    AstraZeneca — Marketing Organization

  3. Jul 20, 2011

    AstraZeneca — NDA Organization

  4. Sep 4, 2018

    Watson Pharmaceuticals — Marketing Organization

  5. Sep 4, 2018

    Allergan PLC (2015) — Marketing Organization

  6. Nov 6, 2018

    Prinston Inc — Marketing Organization

  7. Nov 9, 2018

    Alkem Labs Ltd — Marketing Organization

  8. Jan 23, 2019

    Amneal Pharmaceuticals — Marketing Organization

  9. Jan 23, 2019

    Zhejiang Hisun Pharmaceutical Co. Ltd. — Marketing Organization

2020s

  1. Apr 6, 2020

    Sunshine Lake Pharma Co., Ltd. — Marketing Organization

  2. Apr 7, 2020

    Sigmapharm Laboratories — Marketing Organization

  3. Apr 7, 2020

    MSN Laboratories — Marketing Organization

  4. Oct 29, 2020

    Dr. Reddy's Laboratories — Marketing Organization

  5. Jul 9, 2021

    Mylan — Marketing Organization

  6. Dec 12, 2022

    Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. — Marketing Organization

  7. May 1, 2025

    Apotex — Marketing Organization

  8. May 2, 2025

    Alembic — Marketing Organization

  9. May 5, 2025

    Invagen Pharms — Marketing Organization

  10. Oct 28, 2025

    Macleods Pharmaceuticals, Ltd — Marketing Organization

  11. Oct 28, 2025

    Sciegen Pharmaceticals — Marketing Organization

  12. Oct 28, 2025

    Taro Pharmaceuticals — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedJul 20, 2011

Chemistry & pharmacology

Loading structure…

SMILES

CCCSC1=NC(N[C@@H]2C[C@H]2C3=CC(F)=C(F)C=C3)=C4N=NN([C@@H]5C[C@H](OCCO)[C@@H](O)[C@H]5O)C4=N1
Mol. weight
522.568 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warning

Sources

Also known as

  • (1s,2s,3r,5s)-3-(7-((1r,2s)-2-(3,4-difluorophenyl)cyclopropylamino)-5-(propylthio)-3h-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  • (1s,2s,3r,5s)-3-(7-((1r,2s)-2-(3,4-difluorophenyl)cyclopropylamino)-5-(propylthio)-3h-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  • 3-(7-((2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3h-(1-3)-triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  • ar-c126532xx
  • ar-c126532xx
  • azd6140
  • azd6140
  • azd6140
  • azd 6140
  • azd 6140
  • azd-6140
  • azd-6140
  • azd-6140
  • brilinta
  • brilinta
  • brilinta
  • brilinta
  • brilinta
  • brilinta
  • brilique
  • brilique
  • brilique
  • brilique
  • brilique
  • possia
  • tiacrelor
  • ticagrelor
  • ticagrelor
  • ticagrelor
  • ticagrelor
  • ticagrelor
  • ticagrelor
  • ticagrelor
  • ticagrelor
  • ticagrelor
  • ticagrelor
  • ticagrelor
  • ticagrelor

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07257198Phase 3Mar 1, 2026University of Montreal
NCT07080684Phase 4Dec 1, 2025University of Messina
NCT06853535Phase 3Apr 1, 2025Fudan University, Sichuan University
NCT06981390N/AFeb 1, 2025Jilin University
NCT06714526N/AJan 31, 2025University of Toronto
NCT06756945Phase 4Jan 31, 2025Capital Medical University
NCT06691191Phase 4Jan 1, 2025University of Florida
NCT06653348Phase 2/Phase 3 (Phase 3)Dec 1, 2024Mazandaran University of Medical Sciences
NCT06588595Phase 4Nov 1, 2024University of Florida
NCT06613191Phase 4Oct 1, 2024Ochsner Health System
NCT06584812Phase 1Sep 9, 2024Government of China
NCT06561867Phase 3Aug 30, 2024Kafrelsheikh University
NCT06671470Phase 1Aug 22, 2024Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
NCT06554821Phase 1Aug 5, 2024AstraZeneca, Parexel
NCT06509893Phase 4Aug 1, 2024Shiraz University
NCT06486363Phase 4Aug 1, 2024Nanjing University
NCT06451198Phase 4Jul 1, 2024Fudan University
NCT06233266Phase 1Jun 18, 2024Bio-innova Co., Ltd
NCT06316570Phase 3Apr 3, 2024Capital Medical University
NCT06228456Phase 4Apr 1, 2024University of Florida
Showing 20 of 407 trials
Page 1 / 21

Organizations

Research & Development (305)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AstraZenecaFor profit904352006
University of FloridaAcademic/Hospital212142012
Capital Medical UniversityAcademic/Hospital141142013
University of PatrasAcademic/Hospital121222011
Harbin Medical UniversityAcademic/Hospital111122014
Kafrelsheikh UniversityAcademic/Hospital101012019
Nicolaus Copernicus UniversityAcademic/Hospital10922014
Nanjing Medical UniversityAcademic/Hospital9932013
People's Liberation Army of ChinaGovernment9332013
Dong-A UniversityAcademic/Hospital7732014
Harvard UniversityAcademic/Hospital7232013
Icahn School of Medicine at Mount SinaiAcademic/Hospital7622012
IQVIAFor profit7032011
University of OttawaAcademic/Hospital7522013
China Medical UniversityAcademic/Hospital6432014
Chinese Academy of Medical SciencesAcademic/Hospital6422013
Jiao Tong UniversityAcademic/Hospital6622014
University of UlsanAcademic/Hospital6432013
University of ViennaAcademic/Hospital6532010
Yonsei UniversityAcademic/Hospital6622013
305 organizations
Page 1 / 16

Marketing (24)

OrganizationOrg typeRelationshipDate
AlembicFor profitMKTGMay 2, 2025
Alkem Labs LtdFor profitMKTGNov 9, 2018
Allergan PLC (2015)For profitMKTGSep 4, 2018
Amneal PharmaceuticalsFor profitMKTGJan 23, 2019
Amneal PharmaceuticalsFor profitSYNJan 23, 2019
ApotexFor profitMKTGMay 1, 2025
AstraZenecaFor profitMKTGJul 20, 2011
AstraZenecaFor profitNDAJul 20, 2011
Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.For profitMKTGDec 12, 2022
Dr. Reddy's LaboratoriesFor profitSYNOct 29, 2024
Dr. Reddy's LaboratoriesFor profitMKTGOct 29, 2020
Invagen PharmsFor profitMKTGMay 5, 2025
MSN LaboratoriesFor profitMKTGApr 7, 2020
Macleods Pharmaceuticals, LtdFor profitMKTGOct 28, 2025
MylanFor profitMKTGJul 9, 2021
Prinston IncFor profitMKTGNov 6, 2018
Prinston IncFor profitSYNAug 16, 2024
Sciegen PharmaceticalsFor profitMKTGOct 28, 2025
Sigmapharm LaboratoriesFor profitMKTGApr 7, 2020
Sunshine Lake Pharma Co., Ltd.For profitMKTGApr 6, 2020
Sunshine Lake Pharma Co., Ltd.For profitMKTGApr 6, 2020
Taro PharmaceuticalsFor profitMKTGOct 28, 2025
Watson PharmaceuticalsFor profitMKTGSep 4, 2018
Zhejiang Hisun Pharmaceutical Co. Ltd.For profitMKTGJan 23, 2019